LUPIN (Lupin Ltd.): Acquisition / M&A
Lupin Ltd. informed the exchange on 21 July that its wholly owned U.S. subsidiary, Lupin Inc., has entered into a licensing agreement in exchange for 332,000 common shares of Kaveri Therapeutics, Inc. U.S.A., according to an NSE filing. The healthcare company has been active on the corporate action front this month, with earlier announcements including EMA approval for NaMuscla® expansion for pediatric indication and updates on its Philippines subsidiary's share buyback.
Events like acquisition announcements have historically shown a 48.9% win rate with a net edge of 0.213% across 141 comparable past occurrences in Strota's database. This base rate reflects how similar catalyst types have performed on average, not a forecast for Lupin specifically.
The stock closed at ₹2,478.5 on 20 July, trading 2.02% below its 52-week high of ₹2,529.5 and 34.94% above its 52-week low of ₹1,836.8. It remains above both its 50-day and 200-day moving averages, with a 14-day RSI of 59.5 indicating neutral momentum. Relative volume at 0.91 suggests below-average participation. The company trades at a price-to-earnings ratio of 21.27 and price-to-book of 5.05, with return on equity at 26.9%.
The filing establishes the licensing arrangement and share exchange; it does not indicate the financial terms of the deal, the therapeutic area involved, or any revenue contribution timelines. The 21 July headline from scanx.trade, published 13 minutes prior to this data timestamp, separately noted that a Lupin subsidiary had acquired an 82.2% stake in Kaveri Therapeutics, though this percentage does not appear in the exchange filing itself.
The catalyst
Lupin Limited has informed the Exchange about Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeutics, Inc. U.S.A. (filing · NSE)
What the data shows after this event
Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.
LUPIN right now
trading +1.78% on the day; P/E 21.27; RSI 59.5. Full LUPIN analysis →
Sources
- Lupin Limited has informed the Exchange about Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeutics, Inc. U.S.A. — NSE
- Lupin subsidiary acquires 82.2% stake in Kaveri Therapeutics — scanx.trade
- Lupin Share Price Today, Lupin Stock Price Live NSE/BSE Updates — The Economic Times
- Neutral Lupin Ltd for the Target Rs.2,520 by Motilal Oswal Financial Services Ltd — Investment Guru India
- Why Lupin shares downgraded to 'Hold' despite robust Q4 PAT growth | Target price — Business Today
Keep digging
- LUPIN — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.